The discovery of a new KCC2 potentiator class is significant because these compounds provide a new set of tools to further the investigation of KCC2’s therapeutic potential in a host of neurological disorders with tremendous unmet medical need. This evidence concerns the gene SLC12A5 and nervous system disorder.